Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

$CTIX - The science is advancing without hype/hope.

There should be a couple of additional trials listed here soon:
https://clinicaltrials.gov/ct2/results?term=cellceutix

The Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation for Brilacidin as a new treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) ahead of its meeting this month with Cellceutix regarding Cellceutix’s planned Phase 3 trial of Brilacidin for ABSSSI. Brilacidin, the Company’s lead drug in a new class of antibiotics called defensin-mimetics, completed a Phase 2b trial in September showing, amongst other things, a single dose of Brilacidin to be as effective in treatment of ABSSSI as a FDA-approved seven-day dosing regimen of daptomycin.
http://cellceutix.com/cellceutix-antibiotic-brilacidin-receives-qidp-designation-from-fda/#sthash.PL5ZKDmA.dpbs

The Company’s Phase 2 clinical trial of Brilacidin-OM for oral mucositis, an often debilitating effect of certain cancer therapies, is targeted for December 2014. Procedural work is being conducted at University of Texas MD Anderson Cancer Center as well as other clinical sites participating in the study.
http://cellceutix.com/patient-enrollment-in-cellceutix-phase-2-clinical-trial-of-brilacidin-om-for-oral-mucositis-targeted-to-begin-in-december-2014/#sthash.Vv5F5oLl.dpbs

The US Food and Drug Administration (FDA) has agreed that Cellceutix may begin a Phase 2 study of Prurisol (abacavir acetate), a potential chronic oral therapy for the treatment of placque psoriasis.
http://cellceutix.com/cellceutix-prurisol-for-psoriasis-fda-agrees-that-phase-2-study-may-begin/#sthash.E7EoWXXH.dpbs

A research collaboration with Fox Chase Chemical Diversity Center (“FCCDC”)(http://www.fc-cdci.com) has led to the award of a Phase 2B Small Business Innovation Research (SBIR) grant to FCCDC from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institute of Health (NIH). The SBIR grant is for up to $1.5 million over two years and research will be directed at developing the Cellceutix technology platform on host defense protein (HDP) mimics for treatment of disseminated fungal infections, particularly those caused by Candida species.
http://cellceutix.com/cellceutix-anti-fungal-compounds-awarded-1-5-million-sbir-grant/#sthash.VwWZwDOv.dpbs

"Enrolling the tenth cohort in the Kevetrin trial"
"material transfer of Brilacidin to a major pharma company for investigation in prevention of infection in implanted devices"
http://cellceutix.com/cellceutix-december-to-be-momentous-month-in-companys-history/#sthash.OAlm7g4f.dpbs

Biotechs at this stage don't usually have earnings. All you can look at is the science advancing. It has done so with minimal dilution.

Four year monthly chart shows overall uptrend:









In Reply to 'Rdunn88'
I'm amazed how anyone can do technical charting on an OTCBB stock with no earnings? This stock is all based on hype/hope until they pass their tests and eventually have sales.